HP2 LABORATOIRE

What HP2 LABORATOIRE does

HP2 Laboratoire (Laboratoire Hypoxie et Physiopathologies cardiovasculaires et respiratoires) is a public university research laboratory jointly supervised by Université Grenoble Alpes (UGA) and Inserm, with clinical operations embedded at CHU Grenoble Alpes. The lab investigates the physiopathological mechanisms of hypoxia — both continuous and intermittent — and their cardiovascular, respiratory, and metabolic consequences, with a primary clinical focus on sleep apnea syndrome (OSA, CSA, OHS) and comorbid chronic respiratory failure. It operates three research teams: a Clinical Team led by Pr. Jean-Louis Pépin and Pr. Renaud Tamisier, a Basic Science Team led by Pr. Diane Godin-Ribuot, and a Hypoxia-Exercice Team led by Pr. Samuel Vergès.

The laboratory's core technological platform is the HypE technical core — an IBiSA-labeled facility that performs controlled hypoxia exposure on humans (via mask and tent systems), rodents, and cells, including a Europe-unique intermittent hypoxia device developed with a local industrial partner. From 2025, HP2 occupies more than 1,000 m² within the new CRESI (Centre de Recherche en Santé Intégrée) at La Tronche, a 6,304 m² facility co-tenanted with TIMC and AGEIS laboratories and backed by a €20 million public investment, adding dedicated Exercise, Sleep, and Hypoxic Exposure platforms. The clinical program enrolls more than 800 patients per year in trials and contributes to large national and European registries (MARS n>2,500; OSFP national cohort n=100,000; ESADA).

HP2 is a non-profit academic institution with no commercial revenue model. Operating funding comes from public research grants and institutional support from UGA, Inserm, and CHU Grenoble Alpes, supplemented by European and competitive national programs. The lab's "outputs" are peer-reviewed publications, trained researchers (~20 PhD students, ~5 post-docs at any given time), clinical innovations transferred to hospital practice, and field-research collaborations including Expedition 5300 in Peru and a historical partnership with Harvard University. Its "customers" are therefore patients participating in trials, graduate students, and the broader scientific and clinical community rather than commercial buyers.

Name

HP2 LABORATOIRE

Legal name

Laboratoire Hypoxie et Physiopathologies cardiovasculaires et respiratoires (HP2)

Website

https://hp2.univ-grenoble-alpes.fr

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

HP2 Laboratoire is a public French research laboratory (UGA / Inserm) that studies hypoxia, sleep apnea syndrome, and cardiovascular-respiratory physiopathology, operating the HypE technical core platform and enrolling 800+ patients annually in clinical trials.

Ownership category

akta.pro rank

Product category

Academic Research (Hypoxia and Respiratory/Cardiovascular Physiopathology)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAKANAN

Occupational & Environmental Lung Disease Clinic

Healthcare & Life Sciences/Specialist Medical Practice/Pulmonology & Sleep Medicine

Keywords

• Hypoxia physiology research
• Sleep apnea research
• Cardiovascular physiopathology
• Translational medicine research
• Altitude exercise physiology

Headquarters

HQ city

La Tronche

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Public Research Funding: HP2 Laboratory operates as a public research laboratory under the supervision of Université Grenoble Alpes (UGA) and Inserm. Funding comes from public sources including government research grants, institutional support from supervising organizations (UGA, Inserm, CHU Grenoble Alpes), and potentially European research projects. No commercial revenue model as this is a non-profit academic research institution.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

HP2 Laboratoire is a public academic research laboratory that conducts fundamental, translational, and clinical research on hypoxia (continuous and intermittent), sleep apnea syndrome, and cardiovascular/respiratory physiopathology. The laboratory operates three research teams (Clinical, Basic Science, Hypoxia-Exercise), runs the IBiSA-labeled HypE technical core hypoxia exposure platform, conducts clinical trials enrolling 800+ patients annually, and trains graduate students (Masters and PhDs). It also develops unique hypoxia exposure devices in partnership with a local industrial partner.

Product overview

HP2 LABORATOIRE is a research laboratory specializing in hypoxia and cardiovascular/respiratory physiopathology. The laboratory operates as an integrated research ecosystem comprising three research teams (Clinical, Basic Science, and Hypoxia-Exercise), the CRESI research center housing state-of-the-art platforms for exercise, sleep, and hypoxia research, and the HypE technical core facility providing specialized hypoxia exposure services. The laboratory conducts translational research from healthy volunteers to patients, combining physiology, biology, clinical research, and data sciences.

Differentiator

Problem solved

Functional benefit

Brands

• HypE (Plateforme d'hypoxie HypE): The HypE (Hypoxie) technical core performs various hypoxia exposures on humans, rodents, and cells to study body adaptations or maladaptations to hypoxia. It is IBiSA-labeled.
• CRESI (Centre de Recherche en Santé Intégrée)
• CRESI

Products and services

• CRESI (Centre de Recherche en Santé Intégrée) A multidisciplinary research center at La Tronche campus dedicated to health innovation, housing HP2 Laboratory together with TIMC, AGEIS, and additional institutions; provides state-of-the-art platforms for exercise, sleep, and hypoxia research, supporting researchers and clinicians around unique research platforms.
• HypE Technical Core (Plateforme d'hypoxie HypE) IBiSA-labeled technical core facility at HP2 that performs hypoxia exposure experiments on humans (via mask and hypoxia tent), rodents, and cells. Supports continuous and intermittent hypoxia protocols (including FiO2 switching from 21% down to 5% once per minute) and normoxic control conditions for studying body adaptations or maladaptations to hypoxia.
• Exercise-Physical Activity Platform Research platform within CRESI for exercise exploration, cardio-metabolic and neuromuscular assessment, exercise training, and therapeutic intervention studies, supporting the Hypoxia-Exercice team's research program.
• Sleep Platform Research platform within CRESI dedicated to sleep exploration, diagnosis, and management of sleep-related respiratory disorders, supporting the Clinical Team's research on sleep apnea syndrome.
• Hypoxic Exposure Platform Dedicated facility for exposing healthy subjects and patients to hypoxia in controlled conditions, including continuous or intermittent hypoxia at rest, during effort, and during sleep, supporting HP2 hypoxia research across all three teams.

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Nine partnerships are on record, tiered core and major.

• Université Grenoble Alpes (UGA)coreStrategic or Co-development PartnerUGA is one of the two main supervising institutions of HP2 Laboratory. As a major player in higher education and research in France, UGA provides institutional framework, infrastructure, and academic programs. UGA features in top 100-200 of major international rankings (Reuters, Shanghai, Times Higher Education, QS).
• Inserm (Institut national de la santé et de la recherche médicale)coreStrategic or Co-development PartnerInserm is the French public research institute focused entirely on human health. It provides strategic, scientific and operational coordination of biomedical research. Inserm supervised HP2 as part of its research network.
• CHU Grenoble AlpescoreStrategic or Co-development PartnerWith more than 2,100 beds, CHUGA is the 12th largest hospital in France. It provides clinical research facilities, patient access, and state-of-the-art core facility for HP2. The hospital hosts the lab's clinical research operations and specialized care units.
• IAB - Institute for Advanced BiosciencesmajorStrategic or Co-development PartnerInserm U1209, CNRS UMR5309, UGA - Institute for Advanced Biosciences located in Grenoble focusing on interdisciplinary biological research.
• GIN - Grenoble Institut des NeurosciencesmajorStrategic or Co-development PartnerInserm U1219, UGA - Neurosciences research institute in Grenoble for brain and nervous system research.
• Harvard UniversitymajorStrategic or Co-development PartnerCollaboration with Harvard University on hypoxia tent development for healthy subject exposure studies. Referenced in Tamisier et al., Eur Respir J 2011 publication.
• Chaire E-santémajorStrategic or Co-development PartnerE-health chair focused on studying health factors using multidisciplinary approaches and big data analysis methods. HP2 contributes research on sleep, hypoxia, and chronic disease trajectories.
• Chaire Montagne Altitude SantémajorStrategic or Co-development PartnerMountain and altitude health chair led by Samuel Vergès, focusing on health impacts of high-altitude environments. HP2 Hypoxia-Exercice team conducts research through Expeditions 5300.
• Université Nationale de l'Altiplano (Peru)majorStrategic or Co-development PartnerPartnership for collaborative research on high-altitude populations in Peru, specifically studying endurance athletes in Puno and residents of La Rinconada.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Woolcock Institute of Medical Research: Australian academic medical research institute with a major Sleep and Respiratory Research group focusing on sleep apnea, COPD, and translational respiratory medicine. Comparable in mission to HP2's clinical sleep apnea research program.
• Max Planck Institute for Heart and Lung Research: German basic-research institute studying cardiac, pulmonary, and vascular pathophysiology. Comparable to HP2's Basic Science team's molecular and physiological work on hypoxia and cardiovascular mechanisms.
• University of Pennsylvania Center for Sleep and Circadian Neurobiology: Leading US academic sleep research center with deep programs in sleep-disordered breathing and its cardiovascular and metabolic consequences. Highly comparable to HP2 in combining basic science with clinical sleep apnea research.
• Centre for Altitude, Space and Extreme Environment Medicine (CASE), UCL: Academic research center at University College London specializing in hypoxia, high-altitude physiology, and extreme environment medicine. Directly comparable to HP2's Hypoxia-Exercice team and Expedition 5300 program.
• Charité – Universitätsmedizin Berlin, Interdisciplinary Sleep Medicine Center: Major European academic sleep medicine center with strong clinical trial programs in sleep-disordered breathing and cardiovascular comorbidities. Direct peer to HP2's clinical SAS research and integrated care approach.
• Brigham and Women's Hospital Sleep Medicine Service: Harvard-affiliated sleep medicine program and existing HP2 collaborator. Comparable in clinical SAS research depth and translational focus on cardiovascular consequences of sleep apnea.

Broad incumbents

• Mayo Clinic Center for Sleep Medicine: Established US clinical and research sleep medicine program covering epidemiology, phenotyping, and therapeutic trials. Broad incumbent peer given similar clinical SAS research orientation.
• Stanford Center for Sleep Sciences and Medicine: Large US academic sleep medicine center with broad translational research portfolio and strong industry partnerships. Comparable in research breadth but significantly larger scale than HP2.

Emerging players

• ISGlobal Barcelona Institute for Global Health: European research institute with growing programs in environmental and respiratory health including altitude-related exposures. Partial overlap with HP2's high-altitude populations research.

Others

• European Sleep Research Society (ESRS) affiliated labs network: Pan-European scientific society coordinating sleep research labs including those contributing to the ESADA register accessed by HP2. Ecosystem/network peer reflecting shared research infrastructure.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hp2-laboratoire

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HP2 LABORATOIRE